Advances in bone biology and new treatments for bone loss

Maturitas

Volumn 60, Issue 1, 2008, Pages 65-69

  Gallagher, J Chris ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone biology; Bone loss; Bone remodeling; Ostoporosis

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTHRITIS; BONE DEVELOPMENT; BONE REMODELING; ENZYME ACTIVATION; ENZYME INACTIVATION; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 45649084098     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.04.005     Document Type: Review

References (17)

1. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
2. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 (1998) 3597-3602
3. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
4. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
5. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
6. Tsuda E., Goto M., Mochizuki S.I., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234 (1997) 137-142
7. Burgess T.L., Qian Y.X., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145 (1999) 527-538
8. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
9. Kong Y.-Y., Feige U., Sarosi I., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
10. Capparelli C., Li J., Elliott R., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304309
11. Gravallese E.M., Manning C., Tsay A., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43 (2000) 250-258
12. Haynes D.R., Crotti T.N., Loric M., Bain G.I., Atkins G.J., and Findlay D.M. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40 (2001) 623-630
13. Jones D.H., Kong Y.Y., and Penninger J.M. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61 Suppl. 2 (2002) ii32-ii39
14. Bekker P.J., Holloway D., Nakanishi A., et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 (2001) 348-360
15. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19 (2004) 1059-1066
16. McClung M.R., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831
17. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res (2007, August 20) [online]